In this systematic review of published and ongoing clinical trials of the efficacy of GLP‐1RAs for NAFLD, we found that GLP‐1 RAs are effective for the improvement in hepatic enzymes and hepatic steatosis, with the potential to reverse fibrosis. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.